{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:26Z","timestamp":1790794766291,"version":"4.1.0"},"reference-count":47,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Aggressive tumors are treated with surgery, radiation, chemotherapy, targeted therapy, and various immunotherapies. Cancer immunotherapies under investigation encompass monoclonal antibodies, including checkpoint inhibitors, bispecific antibodies, and T cell redirecting antibodies, as well as gene-modified cell therapies such as CAR-T cells, donor lymphocyte infusions (DLI), antigen-specific DLI, and TCR-engineered T cells. While dendritic cell (DC)-based vaccines derived from peripheral blood have shown promise in preclinical studies, clinical trials have been less effective. Recently, a novel allogeneic DC vaccine has been developed using CD34+ hematopoietic stem cells (HSCs), which are engineered to overexpress CD93, CD40 ligand (CD40L), and CXCL13, thereby enhancing immune activation and improving scalability and effectiveness. This approach has shown potential in controlling tumor growth by stimulating the immune system in preclinical studies. This commentary highlights the promise of engineered allogeneic DC vaccines, their benefits over autologous methods, and the challenges of clinical translation. Combining this DC vaccine with checkpoint inhibitors and refining its design could make it a game-changing off-the-shelf cancer therapy.<\/p>","DOI":"10.1615\/critrevimmunol.2025061548","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T18:29:23Z","timestamp":1760725763000},"page":"45-51","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Dendritic Cells: Transforming the Impact of Cancer Immunotherapy"],"prefix":"10.1615","volume":"46","author":[{"given":"Saleemulla","family":"Mahammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahid","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawaljit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Aerts JG, de Goeje PL, Cornelissen R, Kaijen-Lambers ME, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FA, Waasdorp C, Braakman E. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: From mouse to human. Clin Cancer Res. 2018;24(4):766\u201376.","DOI":"10.1158\/1078-0432.CCR-17-2522"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245\u201352.","DOI":"10.1038\/32588"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, Lee KB, Alexander KA, Rogers BE, Murphy KM, Hawkins WG, Fields RC, DeSelm CJ, Schwarz JK, De-Nardo DG. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37(3):289\u2013307.e9.","DOI":"10.1016\/j.ccell.2020.02.008"},{"key":"4","unstructured":"Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955\u201364."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, Suehiro Y, Yamasaki T, Hinoda Y, Oka M. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med. 2014;12:175.","DOI":"10.1186\/1479-5876-12-175"},{"key":"6","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D\u2019Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2 23;9(1):112\u201321."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38\u201348.","DOI":"10.1016\/j.immuni.2013.07.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Steinman RM. Decisions about dendritic cells: Past, present, and future. Annu Rev Immunol. 2012;30:1\u201322.","DOI":"10.1146\/annurev-immunol-100311-102839"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","DOI":"10.1038\/s41577-019-0210-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016;4:14.","DOI":"10.1186\/s40425-016-0119-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","DOI":"10.1097\/CJI.0b013e3181eec14c"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Ikewaki N, Kulski JK, Inoko H. Regulation of CD93 cell surface expression by protein kinase C isoenzymes. Microbiol Immunol. 2006;50(2):93\u2013103.","DOI":"10.1111\/j.1348-0421.2006.tb03774.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Tossetta G, Piani F, Borghi C, Marzioni D. Role of CD93 in health and disease. Cells. 2023;12(13):1778.","DOI":"10.3390\/cells12131778"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Barbera S, Raucci L, Lugano R, Tosi GM, Dimberg A, Santucci A, Galvagni F, Orlandini M. CD93 signaling via rho proteins drives cytoskeletal remodeling in spreading endothelial cells. Int J Mol Sci. 2021;22(22):12417.","DOI":"10.3390\/ijms222212417"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, L\u00f6\u00f6f J, Trendelenburg G, Essand M, Pont\u00e9n F, Smits A, Dimberg A. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival. Cancer Res. 2015;75(21):4504\u201316.","DOI":"10.1158\/0008-5472.CAN-14-3636"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Li D-K, Wang W. Characteristics and clinical trial results of agonistic anti\u2011CD40 antibodies in the treatment of malignancies (Review). Oncol Lett. 2020;20(5):176.","DOI":"10.3892\/ol.2020.12037"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Banchereau J, Bazan F, Blanchard D, Bri\u00e8re F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881\u2013922.","DOI":"10.1146\/annurev.iy.12.040194.004313"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Elwakeel A, Bridgewater HE, Bennett J. Unlocking dendritic cell-based vaccine efficacy through genetic modulation-how soon is now? Genes. 2023;14(12):2118.","DOI":"10.3390\/genes14122118"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, Clark EA. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol. 1996;157(10):4363\u201370.","DOI":"10.4049\/jimmunol.157.10.4363"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt\u2019s lymphoma receptor-1. Nature. 1998;391(6669):799\u2013803.","DOI":"10.1038\/35876"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5. J Exp Med. 1998;187(4):655\u201360.","DOI":"10.1084\/jem.187.4.655"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Gao SH, Liu SZ, Wang GZ, Zhou GB. CXCL13 in cancer and other diseases: Biological functions, clinical significance, and therapeutic opportunities. Life. 2021;11(12):1282.","DOI":"10.3390\/life11121282"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Vissers JL, Hartgers FC, Lindhout E, Figdor CG, Adema GJ. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol. 2001;31(5):1544\u20139.","DOI":"10.1002\/1521-4141(200105)31:5<1544::AID-IMMU1544>3.0.CO;2-I"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Huerta-Yepez S, Gonzalez JD, Sheik N, Beraki S, Kathirvel E, Rodriguez-Frandsen A, Chen PC, Sargsyan T, Mahammad S, Dybul MR, Chen L, Binette F, Jewett A. Therapeutic efficacy of CD34-derived allogeneic dendritic cells engineered to express CD93, CD40L, and CXCL13 in humanized mouse models of pancreatic cancer. Vaccines. 2025;13(7):749.","DOI":"10.3390\/vaccines13070749"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Hannani D, Leplus E, Laulagnier K, Chaperot L, Plumas J. Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. Genes Cancer. 2023;14:3\u201311.","DOI":"10.18632\/genesandcancer.229"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Wang C, Li Z, Zhu Z, Chai Y, Wu Y, Yuan Z, Chang Z, Wang Z, Zhang M. Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1+CD8 T cells. Sci Rep. 2019;9(1):15527.","DOI":"10.1038\/s41598-019-52151-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Fr\u00f6bom R, Berglund E, Berglund D, Nilsson IL, \u00c5hl\u00e9n J, von Sivers K, Linder-Stragliotto C, Suenaert P, Karlsson-Parra A, Br\u00e4nstr\u00f6m R. Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors. Cancer Immunol Immunother. 2020;69(11):2393\u2013401.","DOI":"10.1007\/s00262-020-02625-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3.","DOI":"10.1186\/s40164-022-00257-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Burkhardt C, B\u00fchler L, Viertl D, Stora T. New isotopes for the treatment of pancreatic cancer in collaboration with CERN: A mini review. Front Med. 2021;8:674656.","DOI":"10.3389\/fmed.2021.674656"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy\u2014An overview. Curr Radiopharm. 2013;6(3):152\u201380.","DOI":"10.2174\/18744710113066660023"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, sukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms\u2019 tumor 1 (WT1)-specific MHC class I\/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20(16):4228\u201339.","DOI":"10.1158\/1078-0432.CCR-14-0314"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Tran LC, \u00d6zdemir BC, Berger MD. The role of immune checkpoint inhibitors in metastatic pancreatic cancer: Current state and outlook. Pharmaceuticals. 2023;16(10): 1411.","DOI":"10.3390\/ph16101411"},{"key":"33","doi-asserted-by":"crossref","unstructured":"van Gulijk M, Dammeijer F, Aerts J, Vroman H. Combination strategies to optimize efficacy of dendritic cell-based immunotherapy. Front Immunol. 2018;9:2759.","DOI":"10.3389\/fimmu.2018.02759"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Van Zeeburg H, Wagner Drouet E, Platzbecker U, Holderried TAW, Van Elssen C, Giagounidis A, Lehmann S, Rovers J, Gjertsen BT, van de Loosdrecht AA. Vaccination using an allogeneic leukemia-derived dendritic cell vaccine, maintains and improves frequencies of circulating antigen presenting dendritic cells correlating with relapse free and overall survival in AML patients. Blood. 2023;142(Suppl 1):2957.","DOI":"10.1182\/blood-2023-188573"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Deuse T, Schrepfer S. Progress and challenges in developing allogeneic cell therapies. Cell Stem Cell. 2025;32(4):513\u201328.","DOI":"10.1016\/j.stem.2025.03.004"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Plumas J, Alvez P, Chaperot L, Hannani D. Priming and expansion of neo-antigen specific-T cells thanks to an off-the-shelf cell-based drug product. Annals Oncol. 2017;28:xi18\u20139.","DOI":"10.1093\/annonc\/mdx711.045"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing dendritic cell cancer vaccination: The synergy of immune checkpoint inhibitors in combined therapies. Int J Mol Sci. 2024;25(14):7509.","DOI":"10.3390\/ijms25147509"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954.","DOI":"10.1016\/j.biopha.2023.114954"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2017;38(8):577\u201393.","DOI":"10.1016\/j.it.2017.05.006"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.","DOI":"10.1177\/20503121211069012"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020;11:940.","DOI":"10.3389\/fimmu.2020.00940"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Knudsen NH, Manguso RT. Tumor-derived PGE2 gives NK cells a headache. Immunity. 2020;53(6):1131\u20132.","DOI":"10.1016\/j.immuni.2020.11.018"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012;72(6):1407\u201315.","DOI":"10.1158\/0008-5472.CAN-11-2544"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461.","DOI":"10.1016\/j.ctrv.2022.102461"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","DOI":"10.1038\/s41423-024-01207-0"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","DOI":"10.1186\/s13046-021-02148-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities. BioDrugs. 2019;33(1):45\u201360.","DOI":"10.1007\/s40259-018-0324-z"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/1c2bcb4473318bdc\/CRI(5)-61548 Kaur.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:32:28Z","timestamp":1790793148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,3cd8f7141fb7b275,1c2bcb4473318bdc.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2025061548","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}